SECOND QUARTER IN BRIEF Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3) Active Biotech acquired exclusive rights to patents of tasquinimod in combination therapy in multiple myeloma (May 22) Clinical activity and safety of naptumomab and docetaxel in non-small cell lung cancer…
SECOND QUARTER IN BRIEF Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (April 19) Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (May 26) Positive safety and tolerability in…
SECOND QUARTER IN BRIEF Laquinimod eye drop phase I single ascending-dose part in healthy subjects was completed without reported safety concerns, multiple-dose part started Active Biotech strengthened the patent protection for laquinimod in eye disorders (April 26) FDA granted Orphan Drug Designation for tasquinimod in myelofibrosis (May 18) Successful completion…
Good progress in the projects towards important clinical events SECOND QUARTER IN BRIEF Active Biotech and NeoTX announce FDA clearance of IND for phase II clinical trial of naptumomab EVENTS AFTER THE END OF THE PERIOD Active Biotech provided status update on the progress in its clinical naptumomab project Active…
Second quarter in brief Dr Elaine Sullivan, Dr Aleksandar Danilovski and Dr Axel Glasmacher were appointed as new members of the Board at the Annual General Meeting on May 19 Active Biotech provided status update in the portfolio projects New…
Significant events during the second quarter In accordance with the Board’s proposal, the Extraordinary General Meeting on April 4, 2019, resolved to approve the sale of the company’s property to Estea AB Active Biotech completed the sale of the property, Forskaren 1, to Estea AB on…
Second quarter in brief The company’s partner NeoTX presented new preclinical data for ANYARA at the AACR Annual Meeting in Chicago The rights issue in April brought the company SEK 47.1 M Events after the end of the period The company announced that the Phase II LEGATO-HD trial…
Second quarter in brief In April, the US Food and Drug Administration (FDA) granted Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma The primary clinical endpoint from the Phase III trial of laquinimod in RRMS (CONCERTO study) was not met. The secondary endpoints (brain atrophy, relapse rate…
Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from both the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected…
· Operations focused on the laquinimod projects and organization adjusted accordingly Laquinimod· The pivotal CONCERTO clinical Phase III study in relapsing remitting MS (RRMS) is fully enrolled and results are expected in 2017· The first patient was enrolled for the ARPEGGIO Phase II study, which will evaluate laquinimod’s potential for treatment of primary…
Laquinimod On May 23, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) reaffirmed its negative opinion on the market application for laquinimod (Nerventra®) CHMP confirmed that the risks observed in animal studies do not prevent a registration for treatment in humans The ongoing US pivotal clinical…
Events during January – June 2013: Laquinimod · positive results from Phase IIa study of laquinimod in active lupus nephritis· Teva plans continued clinical development of laquinimod for the treatment of lupus nephritis· data presented at AAN showed a slower disability progression for multiple sclerosis patients who commenced early treatment with laquinimod compared…
* Laquinimod – application submitted for regulatory approval in the EU resulting in milestone payment of USD 5 M during third quarter 2012 – a Phase III study will be initiated in the US * TASQ – milestone payment of EUR 10 M received from Ipsen in connection with meeting patient enrolment target for Phase…
· Laquinimod – results of Phase III BRAVO trial reinforce unique profile of laquinimod for multiple sclerosis treatment · TASQ – recruitment of patients for the Phase III trial ongoing · TASQ – partnership agreement initiated with Ipsen · ANYARA – Phase III trial continues according to plan · 57-57 – preparation for the start of the SSC exploratory…
